Medicine Invented in Finland Conquers the World – Company’s Stock Price on the Rise
Orion’s Nubeqa cancer drug already has marketing authorization in 85 countries.
Pharmaceutical company Orion’s stock price has been on a robust upward trend for less than a year. Orion’s B-share has climbed from around 33 euros in mid-April last year to approximately 54 euros.
Few Finnish listed companies have been able to present such impressive figures recently.
Behind this is the global success of the Nubeqa prostate cancer drug, jointly developed by Orion and its German partner Bayer.